Eves

Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs

IRVING, Texas--(BUSINESS WIRE)--Jul 11, 2007 - The Journal of theAmerican Society of Clinical Oncology has published the earlyresults of a clinical study conducted by Dr. Siu-Fun Wong, and hercolleagues, which concluded that the topical gel, Regenecare(R),caused a statistically significant reduction in the pain anditching of a rash that results from the use of anti-cancer drugsknown as EGFR...

Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial

CHICAGO, June 21, 2007 /PRNewswire-FirstCall/ -- Advanced LifeSciences Holdings, Inc. , today announced positive results fromTrial CL-06, the first of two pivotal Phase 3 clinical trialsdesigned to assess the safety and effectiveness of cethromycin, anovel once-a-day antibiotic, for the treatment of communityacquired pneumonia (CAP). In the study, cethromycin achievednon-inferiority in i...

Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur

- Blood pressure reduction achieved at 8 am versus placebo: - 25/ - 13 mm Hg (systolic / diastolic, p - Blood pressure reduction dependent on vaccine dose and inducedantiangiotensin II antibody levels - Detailed results presented today at the Seventeenth EuropeanMeeting on Hypertension in Milan, Italy SCHLIEREN (Zurich), Switzerland and MILAN, Ita...

Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)

Preliminary Results of Largest Randomized, Placebo-controlled TrialEver Conducted in CTCL Presented at the American Society ofClinical Oncology CHICAGO, June 04, 2007 /PRNewswire/ -- Preliminary results ofthe largest randomized, placebo-controlled clinical trial everconducted in patients with cutaneous T-cell lymphoma (CTCL) showedthat ONTAK was more than twice as effective as placebo in...

Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune

CARLSBAD, Calif., April 23, 2007 /PRNewswire-FirstCall/Micromet, Inc. today announced the achievement of a milestone inits research collaboration with MedImmune, Inc. for the developmentof new BiTE(R) molecules targeting carcinoembryonal antigen (CEA),a validated tumor- associated antigen frequently expressed onvarious human carcinomas. Preclinical data recently presented atthe 2007 Annu...

Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease

GENEVA, April 17, 2007 /PRNewswire/ -- Addex Pharmaceuticalsannounced today the successful completion of a Phase IIa proof ofconcept trial with its lead compound ADX10059 in patients withgastro-esophageal reflux disease (GERD), a highly prevalentcondition with a significant unmet medical need. The study achievedits primary objective, the control of 24-hour esophageal pH, withstatistical...

Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine

SAN FRANCISCO, April 11, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that a seasonal influenza vaccineformulated with the company's Vaxfectin(TM) adjuvant generated upto 60-fold higher antibody responses than an unformulated vaccineat the same dose in a recently completed study in mice. Formulationof sanofi pasteur's Fluzone(R) commercial vaccine withVaxfectin(TM) al...

Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model

Mymetics Also Announces Deal for Vaccine Delivery System NYON, Switzerland, March 29, 2007 /PRNewswire-FirstCall/ --Mymetics Corporation announced today that the Company's HIV vaccineelicited IgA mucosal antibodies in a non-human primate model.Mucosal IgA antibodies are considered a possible first line ofdefense against infection by HIV. The data were presented bySylvain Fleury, Ph.D., My...

Integrated Biopharma's Proprietary Vaccine Technology Achieves Strong Positive Results

HILLSIDE, N.J., March 12, 2007 /PRNewswire-FirstCall/ --InB:Biotechnologies, Inc. ("BioTech"), a wholly-owned subsidiary ofIntegrated BioPharma, Inc. , today announced strong positiveresults in studies of vaccines against HPV, anthrax and plague madeusing INBP's novel, proprietary AIPwLV(TM) vaccine technology. Thestudies were conducted by the Fraunhofer USA Center for MolecularBiotechno...

Integrated BioPharma's Proprietary Vaccine Technology Achieves Strong Positive Results

HILLSIDE, NJ, March 12, 2007—InB:Biotechnologies, Inc.("BioTech"), a wholly-owned subsidiary of Integrated BioPharma,Inc. (NASDAQ: INBP), today announced strong positive results instudies of vaccines against HPV, anthrax and plague made usingINBP's novel, proprietary AIPwLV™ vaccine technology. Thestudies were conducted by the Fraunhofer USA Center for MolecularBiotechnology...